In AD, the accumulation of Aβ1–42 and p-tau is thought to become saturated before the onset of symptoms such as cognitive decline and cerebral atrophy, which become apparent later (Weiner et al., 2015). This evidence concerns the gene MAPT and Alzheimer disease.